In a recent study focusing on heart failure patients with hyperkalemia and a high frequency of CKD who were on RAASi therapy, the risk of all-cause death was found to be closely related to RAASi (ACEi, ARBs or mineralocorticoid receptor antagonists [MRAs]) discontinuation rather than to hyperkalemia levels themselves [26]. Here, NR3C2 is linked to chronic kidney disease.